**Pharmacological aspects**

**Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs**

Chin B. Eap, PhD

---

**Introduction**

Psychiatric illnesses are associated with a high prevalence of therapeutic failure, drug-associated side effects, and recurrent conditions. In psychiatry, as in other diseases, there is a high interindividual variability in drug responses for efficacy, tolerability, and safety, which is determined by patient factors such as illnesses, sex, age, ethnicity, and genetic variability, and by environmental factors, including concomitant medication, smoking, and/or diet.1,2 This variability in drug response is affected by variability in pharmacokinetics, ie, drug disposition (absorption, distribution, metabolism and excretion [ADME]), leading to a variability in plasma concentration of the active drug, but also by variability in pharmacodynamics, ie, the interaction of the drug with its target site (such as enzymes, receptors, and transporters).1 Personalized prescribing can be expressed as personalized dosing and/or drug selection, taking into account genetic, as well as environmental and personal, variables.3 This review discusses the present and future use of pharmacogenetics in psychiatry, which, combined with careful clinical evaluations and other tools such as

---

**Keywords:** antidepressant; antipsychotic; cytochrome P450; pharmacodynamic; pharmacogenetic; pharmacogenomic; pharmacokinetic; psychiatry; psychotropic drug; therapeutic drug monitoring
Pharmacological aspects

Selected abbreviations and acronyms
CYP    cytochrome P450
EM     extensive metabolizer
GWAS  genome-wide association study
HLA    human leukocyte antigen
HLA-B  major histocompatibility complex, class I, B
IM     intermediate metabolizer
PM     poor metabolizer
SJS    Stevens-Johnson syndrome
SSRI   selective serotonin reuptake inhibitor
TCA    tricyclic antidepressants
TDM    therapeutic drug monitoring
TEN    toxic epidermal necrolysis
UM     ultrarapid metabolizer

therapeutic drug monitoring (TDM) and phenotyping, can help provide the best care for psychiatric patients. This review is based on arbitrarily selected pharmacogenetic studies. The topic of TDM is covered in detail by a consensus article and is not discussed here. Whereas our review has a stronger focus on the clinical applications and usefulness of pharmacogenetics tests, the article by Eum et al in this issue (p 323) provides a much more detailed elaboration of currently commercially available tests.

Pharmacokinetics genes

Among pharmacokinetics proteins, the members of the cytochrome P450 (CYP) family display large interindividual and interethnic variability in activity, controlling the metabolism of many psychotropic drugs. More than 50 CYP enzymes have been identified in humans, but more than 90% of all drugs are metabolized by only a few of them—CYP1A2, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5. The US Food and Drug Administration (FDA) table of pharmacogenetic markers in drug labels contains more than 135 drugs, a fifth used in psychiatry, most of them CYP2D6-dependent drugs.

Various CYP2D6-activity phenotypes exist, including poor, intermediate, extensive, and ultrarapid metabolizers (PMs, IMs, EMs, and UMs), with PMs having no functional alleles, IMs being heterozygous for an active and an inactive allele or having two alleles with reduced activity, EMs being wild-type with two active alleles, and UMs having an amplification of functional alleles (3 to 13 copies). The PM status can be genotyped, with 5 to 10 single-nucleotide polymorphisms (SNPs) accounting for 95% to 99% of the variability. However, more than 100 variants and subvariants have been described for CYP2D6, with a strong influence by geographic and ethnic factors, which should be taken into account.

Some studies showed that CYP2D6 might influence the metabolism of endogenous compounds, such as the ligand for the cannabinoid receptor anandamide, or the production of serotonin, with a higher platelet serotonin concentration in UMs than in EMs and PMs. It has been suggested that this could lead to variations in personality, neurocognitive function, and vulnerability to psychopathology, including suicidality. Indeed, a high occurrence of the CYP2D6 UM phenotype has been found in suicide cases; this association could be due to failure of treatment with drugs metabolized by CYP2D6 but also to the metabolism of endogenous substrates. However, CYP2D6 is not a useful predictor of psychiatric symptoms and/or disorders.

On the other hand, many studies have shown a strong influence of CYP2D6 activity on the pharmacokinetics of psychotropic drugs. These include drugs for attention-deficit/hyperactivity disorder (eg, atomoxetine); antidepressants, such as tricycles (TCAs) or tetracycles (TeCAs) that are serotonin and/or norepinephrine reuptake inhibitors (eg, amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, or trimipramine), selective serotonin reuptake inhibitors (SSRIs; eg, citalopram, escitalopram, fluoxetine, fluvoxamine, or paroxetine), and serotonin-norepinephrine reuptake inhibitors (SNRI; eg, duloxetine or venlafaxine); other antidepressants (eg, mianserin or mirtazapine); and antipsychotics (eg, aripiprazole, haloperidol, levomepromazine, perphenazine, risperidone, thioridazine, or zuclopenthixol). Of note, the activity of CYP2D6 and other CYP isoforms can be blocked; several compounds, including some of the abovementioned drugs, are strong CYP2D6 inhibitors (eg, levomepromazine, paroxetine, and fluoxetine) and can potentially transform the phenotype from CYP2D6 EM to PM. On the other hand, CYP2D6 activity cannot be induced in contrast to other CYP isoforms (one Website listing drugs with their CYP-mediated metabolism, as well as important metabolic interactions, can be found in ref 18).

Optimal therapeutic ranges for drug concentrations in plasma have been demonstrated for TCAs, such as...
amitriptyline, clomipramine, doxepin, imipramine, and trimipramine, with UM at increased risk of therapeutic failure and PM at increased risk of toxicity (in particular, for cardiac and anticholinergic effects). A higher risk of side effects has been observed in patients with at least one nonfunctional CYP2D6 allele than in those with two functional alleles. The first genotype-based dose recommendations for antidepressants, including amitriptyline, were proposed by Kirchheiner et al in 2001. More recently, the Pharmacogenetics Working Group from the Royal Dutch Association for the Advancement of Pharmacy developed guidelines. Also, the Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health’s Pharmacogenomics Research Network developed a detailed guideline—updated periodically—for CYP2D6 and CYP2C19 genotypes and dosing of TCAs. For example, in the treatment of depression with amitriptyline, the CPIC recommends consideration of an alternative drug for CYP2D6 UM and PMs.

Personal dosing in psychiatry according to CYP genotype is best adapted for TCAs. However, in psychiatry, the impact of such a strategy is limited since the prescription of TCAs has greatly decreased since the introduction of newer antidepressants (TCAs being mainly used nowadays at lower doses for pain management). Personalized prescribing according to CYP2D6 genotype has been proposed for more recent antidepressants, such as SSRIs (eg, paroxetine, fluoxetine), which are first-line treatments for depression, but also for other psychiatric conditions, such as anxiety, panic, and obsessive-compulsive disorders. Therapeutic ranges have also been proposed for these newer antidepressants; however, as they have wider margins of safety in terms of overdose, as well as lower risks for side effects, the specificity and sensitivity are decreased for CYP genotyping tests in regard to prevention of side effects and/or increasing therapeutic response. Drug choice and/or dose adaptations made on the basis of CYP2D6 genotype have also been proposed for other antidepressants, such as SNRIs (eg, venlafaxine), and for typical (eg, perphenazine, thioridazine) and atypical antipsychotics (eg, risperidone, aripiprazole). Of note, several studies found a higher prevalence of psychiatric drug–induced side effects associated with CYP activity, in particular with CYP2D6 PM status; however, most studies investigating an association between CYP2D6 phenotype and/or genotype and treatment response had negative results, though some had positive results.

CYP2C19 is also highly polymorphic with more than 30 described variants, and allele frequencies are strongly influenced by ethnicity. Similarly, PMs, IMs, EMs, and UMs have been described; the UM phenotype might arise from enhanced gene transcription resulting from the *17 allele, possibly increasing metabolism of antidepressants, such as citalopram and escitalopram. In addition, because the QT-inducing potential associated with these two drugs is higher than with other SSRIs, the CYP2C19 PM phenotype could be a risk factor in treatment with escitalopram. Higher amitriptyline and lower nortriptyline plasma concentrations were measured in CYP2C19 PMs and IMs than in EMs. Personalized prescribing of SSRIs according to CYP2C19 genotype has also been proposed. The CPIC also made recommendations for amitriptyline dosing for combined CYP2D6 and CYP2C19 phenotypes; however, as clinical evidence for an additive effect of CYP2D6 and CYP2C19 in tricyclic dosing is sparse, the recommendations are classified as optional.

CYP2B6 metabolizes a fewer number of compounds, which include methadone and bupropion among psychotropic drugs. Its activity is also highly variable between individuals and within individuals because of genetic and environmental factors. CYP2B6 is highly polymorphic, with variants associated with multiple mechanisms (transcriptional regulation, splicing, messenger RNA and protein expression, and catalytic activity). The simultaneous combinations of many variants producing multiple haplotypes, in addition to the large ethnic influence on CYP2B6 polymorphism, complicates its analysis and the interpretation of results. Methadone, a mu-opioid agonist used in pain treatment and for opioid-dependent patients, can prolong the QT interval and carries a risk for ventricular tachyarrhythmia and Torsades de pointes. Methadone is marketed as a 50%/50% mixture of (R)- and (S)-methadone, with few countries (eg, Germany, Austria, and Switzerland) currently having the pure (R)-enantiomer also available. (R)-methadone is the active form on opioid receptors, whereas (S)-methadone blocks more potently the human ether-à-gogo–related gene (hERG) voltage-gated potassium channel, which is responsible for QT-interval prolongation. (S)-methadone is metabolized preferentially by CYP2B6, with multiple genetic polymorphisms helping to explain extreme (S)-methadone plasma lev-

---

315
Pharmacological aspects

CYP2B6 slow metabolizers have longer corrected QT (QTc) intervals during methadone treatment, and slow CYP2B6 metabolism significantly increases the risk for a borderline or prolonged QTc interval (odds ratio, 6.3). In addition, the replacement of (R,S)-methadone by a half dose of (R)-methadone significantly decreases the QTc interval in opioid-dependent patients treated with methadone. Prescription of (R)-methadone instead of the racemate, therefore, decreases (but does not abolish) methadone cardiotoxicity and should also decrease the influence of CYP2B6-decreased metabolism. However, for a number of reasons, CYP2B6 genotyping cannot substitute for an electrocardiogram in the prediction of cardiac arrhythmias and sudden death in methadone patients. Firstly, diminished CYP2B6 activity is associated with many variants and haplotypes (several with yet unknown functions). Secondly, the presence of several pharmacodynamic heart genes and multiple other risk factors (eg, electrolyte disturbances, pharmaceutical or illicit drugs prolonging the QT interval and/or inhibiting methadone metabolism) may confound the conclusions.

CYP1A2 is particularly involved in the metabolism of clozapine or olanzapine—two atypical antipsychotics—and of duloxetin, an SNRI. Clozapine appears to be more promising than other drugs for personalized dosing because several studies have demonstrated an optimal plasma concentration for this drug; furthermore, high plasma levels are associated with a higher risk of convulsions. Some genetic CYP1A2 variants have been associated with low or high clozapine metabolic activity, but these alleles are either rare or have low predictive value. Therefore, CYP1A2 genotyping is currently of little help for most patients. CYP1A2 activity is also controlled by other (non-CYP1A2) genetic factors, including the P450 oxidoreductase and nuclear factors—such as constitutive androstane receptor (CAR), retinoid X receptor α (RXRa), pregnane X receptor (PXR), and vitamin D receptor (VDR)—which are involved in the regulation of constitutive and/or inducible CYP1A2 activity. Genotyping of those additional genes adds little to predicting CYP1A2 variability, possibly due to the influences of other genes and to the environmental influence on CYP1A2 activity. Thus, phenotyping tests (in vivo measurement of the activity using a probe substance, such as caffeine) or TDM are more appropriate for personalized dosing of clozapine or of other CYP1A2-dependent drugs.

Because of its abundance in the intestine and liver, CYP3A—a term that in adults reflects the collective activity of CYP3A4, CYP3A5, and CYP3A7—is responsible for the metabolism of more than 50% of marketed drugs. There is a large overlap of activity between CYP isoforms, potentially reducing the influence of CYP3A genetic heterogeneity on the pharmacokinetics of CYP3A-dependent drugs as a deficiency of one isoform may be partially compensated for by the activity of others. Although rare cases have been described of CYP3A PMs in which there is the simultaneous occurrence of mutations in different isoforms leading to very low or no CYP3A activity, genotyping is of little clinical relevance unless the drug is preferentially metabolized by CYP3A5 (there is no known example in psychiatry). As is the case for CYP1A2, estimation of CYP3A activity is best measured by phenotyping tests, eg, performed with a very low oral dose of midazolam, such a test also integrating the modification of CYP3A activity by environmental factors.

Other pharmacokinetic genes are not discussed in the present review, in particular ABCB1, which encodes for the permeability P-glycoprotein. Although ABCB1 has been investigated in many studies for its influence on pharmacokinetics and on the response to psychotropic drugs, mixed results have been published and evidence is lacking for the clinical use of ABCB1 genotyping in psychiatry. This gene is discussed in more detail in the companion article by Eum et al in this issue.

In summary, pharmacokinetic genotyping can be useful in drug selection and/or for guiding dosing modifications with the aim to personalize dosing. This is especially important for TCAs, which have a well-defined therapeutic window; nowadays, however, this class of drug is seldom prescribed for depression. Even if the impact of such tests is less important for other drugs, such a strategy is based on a sound and legitimate objective to reduce the interindividual variability in drug pharmacokinetics and the risks associated with extreme phenotypes. CYP genotyping appears more useful at the start of treatment than later on; after long-term treatment, the drug best adapted to a particular patient would possibly already have been selected through trial and error, and the drug dose already adapted according to effect. However, some CYP isoform activity (eg, CYP1A2 or CYP3A) is poorly predicted by gene analysis and must be determined by phenotyping. Thus,
pharmacogenetic tests would not replace, but rather complement, other clinical tools, such as TDM, the latter combining the influence of environmental (eg, diet and/or taking of comedicated medications that induce or inhibit activity), genetic (eg, CYP variants), and personal factors (eg, age, sex, weight, and illness) involved in metabolism and transport of drugs. Last but not least, TDM allows the measurement of active metabolites.1

Pharmacodynamic genes for personalized drug selection

Genetic testing of pharmacodynamic factors is presently more promising for preventing rare idiosyncratic adverse drug reactions than for predicting treatment response. Some recent findings linking pharmacogenetic factors with therapeutic response are interesting but need to be replicated.

Response to treatment and pharmacodynamic factors

Because of the common mechanism of many antidepressants—the inhibition of the reuptake of serotonin by the serotonin transporter—polymorphisms in the serotonin-transporter-linked polymorphic region (5-HTTLPR) of the serotonin transporter gene (SLC6A4) have been extensively studied. In particular, the long (l)-allele is associated with a twofold higher expression than the short (s)-allele. Despite some discrepant results, a meta-analysis of 33 studies confirmed the association between the (l)-allele and response to SSRIs and remission in whites, with sex, age, and age at onset of depression modulating the association.50 However, the clinical impact of SLC6A4 genotyping is modest, with a low odds ratio value (around 1.5), and therefore of little clinical help for predicting response. Other genes—including serotonin receptors (5-hydroxytryptamine receptors 1A and 2A [HTR1A, HTR2A]); tryptophan hydroxylase (TPHI), involved in serotonin biosynthesis; serotonin transporter gene functional intron 2 (STIN2), influencing serotonin transporter expression; and brain-derived neurotrophic factor (BDNF), probably involved in antidepressant action—may also modestly modulate antidepressant response.51 The hypothalamic-pituitary-adrenal (HPA) axis has been implicated in antidepressant response; polymorphisms in the FK506 binding protein 5 (FKBP5), which regulates glucocorticoid receptor sensitivity has been associated with rapid response to antidepressant treatment.52 However, this study was followed by others that in some cases supported these findings and in others did not.53

Because dopamine is involved in the neurotransmitter pathophysiology of schizophrenia and because of the antagonist (all antipsychotics) or mixed agonist (aripiprazole) activity of antipsychotics on the dopamine D2 receptor, dopamine receptor and transporter genes have also been investigated. Polymorphisms in the D2 receptor, in particular the -141Ins/Del polymorphism located in the promoter region, were associated with treatment response (lower response for Del allele) in a meta-analysis, but with a modest effect.54 Other significant, but modest, associations were also found with other catecholamine systems, as well as glutamate and γ-aminobutyric acid (GABA) systems, although none of them could be considered clinically discriminant.55

Although topiramate, an antiepileptic drug, has no official indication for the treatment of alcoholism, it reduces drinking and heavy drinking in individuals with alcohol dependence. Topiramate has multiple pharmacologic effects, including the facilitation of GABAergic function and antagonism of glutamate activity at the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid class of glutamate receptor (AMPA) and at kainate receptors, particularly for those containing GluK1 and GluK2 subunits (encoded by GRIK1 and GRIK2, respectively). The efficacy of topiramate for reducing heavy drinking was recently found to be significantly greater than placebo only in GRIK1 rs2832407 C-allele homozygotes.56 If these results are replicated, it would allow identification of heavy drinkers who would probably respond well to topiramate. This is important because there are only a few drugs available for alcoholism treatment, and they have limited success.

A meta-analysis of three genome-wide association study (GWAS) analyses (GENDEP [GENome-based therapeutic drugs for DEPression], MARS [Munich Antidepressant Response Signatures], and STAR*D [Sequenced Treatment Alternatives to Relieve Depression]), examining the association with antidepressant drug response in 2256 individuals of Northern European descent with major depressive disorders, failed to identify reliable predictors of antidepressant treatment.57 A recent GWAS was performed for lithium response in bipolar 1 disorder with 294 patients of Han Chinese descent and replicated in two smaller groups.58 Variations in the gene encoding glutamate decarboxyl-
ase-like protein 1 (GADL1) were found to be associated with response to lithium with an extraordinarily highly significant $P$ value ($P=10^{-37}$). The mechanism by which GADL1 would influence response is unknown, but its involvement in the biosynthesis of GABA is discussed. This finding has to be confirmed in Chinese patients, and other mutations have to be found in Caucasian and black African subjects (there is a low frequency of the variant of interest in these two populations). Interestingly, a recent study pointed to a variant located in a methylated DNA immunoprecipitation sequencing (MeDIP-seq) site in the brain that may have exome-wide significance for treatment remission in depressed Mexican-Americans treated with fluoxetine; this finding suggests that this variant may be involved in epigenetic regulation of neuronal gene expression.\(^{39}\) This study emphasizes the need for pharmacogenetic studies to include epigenetic factors.

**Adverse events and pharmacodynamic factors**

Concerning antipsychotics, dopamine receptor and transporter genes have also been investigated for associations between genetic polymorphisms and antipsychotic-induced side effects, eg, hyperprolactinemia, extrapyramidal symptoms, and weight gain. Some results were inconsistent, whereas others were significant in meta-analyses only and were of low effect size as they needed a high number of patients to reach statistical significance. The discrepant results and/or the weak significant associations observed could be due, in part, to the proportions of classical (higher risk of hyperprolactinemia and extrapyramidal symptoms) and atypical antipsychotics (higher risks of weight gain) differing between studies; thus, the described associations are of weak or modest predictive value.\(^{39}\) For antidepressants, genetic variations in serotonergic mediators (eg, serotonin transporter and receptors), as well as in intracellular signal transduction pathways, have also been extensively studied.\(^{40}\) The results, when replicated, appear to be more related to tolerance and side effects than to the antidepressant response. Evidence and effect sizes that are sufficient to allow clinical applications are lacking.

A large number of psychotropic drugs, including many antipsychotics (eg, clozapine or olanzapine), some mood stabilizers (eg, valproate), and some antidepressants (eg, mirtazapine), have been associated with substantial weight gain and/or other metabolic dysfunctions (eg, obesity, hyperlipidemia, hypertension, and/or diabetes). Drug-induced weight gain and other metabolic symptoms are of major clinical consequence as they contribute heavily to a marked decrease in life expectancy, with the natural mortality rate in psychiatric patients being 1.5- to 2-fold higher than in the general population, mainly due to a twofold higher prevalence of cardiovascular risk factors.\(^{61-63}\) Pharmacogenetics of psychotropic-induced weight gain has been extensively studied through hypothesis-driven candidate gene approaches. The polymorphisms that were the most studied and for which results were best replicated were in dopamine and serotonin receptors.\(^{64}\) Additionally, other genes implicated in leptin-melanocortin pathways (eg, leptin [LEP], leptin receptor [LEPR], melanocortin 4 receptor [MC4R], and neuropeptide Y [NPY]), the endocannabinoid system (cannabinoid receptor type 1 [CNR1]), or genes involved in fatty acid and cholesterol production (scavenger receptor class B type I [SCARB1], insulin-induced gene 2 [INSIG2]) showed an association with weight gain among psychiatric cohorts treated with antipsychotics.\(^{65}\) Recently, research conducted in our department showed other candidate genes coding for enzymes involved in metabolic pathways (phosphoenolpyruvate carboxykinase 1 [PCK1], 11β-hydroxysteroid dehydrogenase [11βHSDW1]), for receptors (melanin concentrating hormone receptor 2 [MCHR2]), and for transcriptional coactivators (CREB-regulated transcriptional coactivator 1 [CRTC1]) involved in energy balance, appetite regulation, and glucose homeostasis.\(^{66-69}\) There is less information on genes associated with antipsychotic-induced diabetes mellitus and hyperlipidemia. A recent GWAS (N=189) identified no associations with antipsychotic-induced weight gain at the genome-wide threshold, but trends for some variants were observed, variants that should be investigated further.\(^{70}\) The occurrence of metabolic effects can be best predicted by a combination of clinical factors (eg, age and baseline body mass index) with multiple genetic factors, possibly aggregated in genetic risk scores.\(^{71}\) However, the value of such combinations in clinical practice remains to be determined.

Presently, the drug in psychiatry with probably the most compelling evidence in support of pharmacogenetic testing is carbamazepine, an anticonvulsant and a mood-stabilizer drug. It can cause Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) reac-
tions, which occur in about 1 to 6 per 10,000 new users in the white population, but the risk is strongly increased in Asian patients. In Asians, major histocompatibility complex, class I, B, allele 1502 (HLA-B*1502 allele) is a predictor of SJS-TEN, with an extraordinarily high odds ratio (odds ratio, 1357, \( P = 1.6 \times 10^{-41} \)). The FDA requires that Asian patients be screened for the presence of HLA-B*1502 before initiating carbamazepine treatment. Because this allele is also present in patients with non-Asian ancestry, and because Asian ancestry can neither be deduced from the family name nor from the physical appearance, the extension of these analyses in all patients has been advocated. Patients carrying this allele should not be treated with carbamazepine unless the benefit clearly outweighs the risk. In a prospective screening for HLA-B*1502 before prescription of carbamazepine in 4877 Asian patients, no SJS-TEN case was observed in the HLA-B*1502-negative patients, whereas 10 cases were expected, based on historical incidence, without screening. The HLA-A*3101 allele has been proposed as a clinically relevant marker to predict hypersensitivity reactions to carbamazepine in whites and Japanese, but has low sensitivity. The positive predictive value and negative predictive value for a HLA-B*1502 screening test in Asians is 1.8% (7.7% in Han only) and 100%, respectively, with 461 patients needing to be tested to prevent one case of SJS-TEN, which is a favorable cost-benefit ratio considering the present cost of genotyping and the severity of the syndrome. The low positive predictive value (referring to the proportion of patients who test positive for HLA-B*1502 and who then develop SJS-TEN) means that many carriers would not suffer from SJS-TEN, which is theoretically not a major concern because other pharmacological alternatives are available. However, the high negative predictive value (referring to the proportion of patients who test negative for HLA-B*1502 and who do not develop SJS-TEN) is valuable when making a decision to select carbamazepine. Lamotrigine, an antiepileptic drug also used for the treatment of depression in bipolar disorders, can also cause TEN. Although lamotrigine-induced TEN has also been associated with variants of the human leukocyte antigen (HLA) system, there are presently insufficient data to justify HLA genetic testing for lamotrigine treatment.

Ciclozpine is considered the most efficient antipsychotic in resistant schizophrenia. Because of the risk of agranulocytosis, it is licensed for use only in schizo-

The use of pharmacogenetics in psychiatry is already challenging because of factors associated with the complexity of psychiatric illness, a high prevalence of comorbidities, difficulties in classification, and overlapping phenotypes. In addition, there are no valid and reliable diagnostic and prognostic biological markers, in contrast with other diseases (eg, blood glucose levels for type 2 diabetes). Finally, psychiatric diseases are polygenic (a recent GWAS study identified 128 independent associations from 108 defined loci with schizophrenia). Concerning pharmacokinetic genes, dose recommendations according to CYP genotypes have been published for several psychotropic drugs. However, due to the low sensitivity of the tests, a very high number of patients must be genotyped to prevent one case of severe side effect and/or nonresponse. This can explain, in conjunction with the low specificity of the tests and the present cost of genetic analysis, why genotyping of pharmacokinetic factors such as CYP isoforms is not currently done in psychiatry on a retrospective basis to understand unusual drug responses. In addition, the activity of specific isoforms (ie, activity of CYP1A2 and CYP3A4) cannot be reliably used because of the multigenic and environmental influences. However, drug selection and dose recommendations made on the ba-
Pharmacological aspects

sis of CYP activity (determined by genotyping and/or phenotyping) remains a legitimate objective. Concerning pharmacodynamic genes, there is presently only one for which there is strong evidence in favor of proposing testing on a routine basis (HLA-B*1502 for carbamazepine). New pharmacogenetic factors using SNP analysis will be discovered in the future, but the influence of other sources of variability—including genetic factors (eg, copy number variants and microRNA), as well as epigenetic factors (eg, histone deacetylation and gene methylation)—must be taken into account.42-50 Because of the very rapid technological advances and the sharply diminishing costs of genetic analysis, pharmacogenomic testing is increasingly used nowadays. However, the substantial differences in the levels of evidence between markers, combined with the low sensitivity and/or specificity for the large majority of them, has to be taken into account. Pharmacogenetic tests are not magic bullets and to be clinically useful they need to be incorporated into a comprehensive pharmacological knowledge of the drug, which includes its pharmacokinetics and pharmacodynamics, its therapeutic window, and its idiosyncratic and dose-related adverse drug reactions. Only when combined with careful clinical evaluation—with the help of other tools, such as TDM and/or phenotyping tests—can pharmacogenetics contribute to the general aim of providing the best care for psychiatric patients.

Conflict of interest/disclosures: C.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. He has received honoraria, for conferences or teaching continuing medical education (CME) courses, from AstraZeneca, Janssen-Cilag, Lundbeck, Merck Sharp & Dohme, Mepha, Otsuka, Servier, and Vi- for Pharma in the past 3 years. He reports no conflict of interest with this publication.

REFERENCES

1. Crettol S, De Leon J, Hiemke C, Eap CB. Pharmacogenomics in psychiatry: from TDM to genomic medicine. Clin Pharmacol Ther. 2014;95(3):254-257.
2. Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006;28(9):735-768.
3. De Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59(2):81-89.
4. Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011;44(6):195-235.
5. Table of pharmacogenomic biomarkers in drug labeling. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Updated May 20, 2015. Accessed February 23, 2016.
6. Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111-122.
7. Hicks JK, Sven JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402-408.
8. CYP2D6 allele nomenclature. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http://www.cypalleles.ki.se/cyp2d6.htm. Updated January 19, 2016. Accessed April 22, 2016.
9. Snider NT, Sikora MJ, Srirad C, Feuerstein TJ, Rae JM, Hollenberg PF. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 450. J Pharmacol Exp Ther. 2008;327(2):538-545.
10. Bertilsson L. CYP2D6, serotonin, and suicide—a relationship? Clin Pharmacol Ther. 2010;88(3):304-305.
11. Kirchheiner J, Henschel HB, Franke L, et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics. 2005;15(8):579-587.
12. Penas-Lledo EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2014;77(4):673-683.
13. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet. 1989;1(8637):555.
14. Penas-Lledo EM, Dorado P, Aguera Z, et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry. 2011;16(7):691-692.
15. Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther. 2011;89(3):352-353.
16. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88(3):354-359.
17. Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2015;277(2):167-177.
18. Interactions medicamentuses, cytochromes P450 et P-glycoprotéine (Pgp). Centre d’informations thérapeutique et de pharmacovigilance. Available at: http://www.hug-ge.ch/sites/interhug/files/structures/pharmacologie_et_toxicologie_cliniques/documents/substrats_et_inhibiteurs_a5.pdf. Published January 2015. Accessed June 8, 2016.
19. Kirchheiner J, Broseen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104(3):173-192.
20. Sven JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
21. PharmGKB. Available at: http://www.pharmgkb.org. Accessed April 22, 2016.
22. Tamminga WA, Werner J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol. 2003;59(1):57-64.
23. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15-27.
24. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72(4):438-452.
25. Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenet. 1999;9:435-443.
26. Salle FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000;10(1):27-34.
Prescripción personalizada: un nuevo modelo médico para el uso clínico de los psicofármacos

Dada la influencia de los factores genéticos en la farmacocinética y farmacodinámica de los medicamentos, el amplio empleo de pruebas farmacogenéticas en psiquiatría ya ha sido propuesta desde los comienzos de los años 2000. Sin embargo, sólo unas pocas pruebas (ej. HLA-B*1502 para la carbamazepina en epilepsia o trastornos bipolares) han alcanzado niveles de evidencia para justificar su uso rutinario, mientras que muchos hallazgos son demasiado preliminares o, cuando se han replicado, son de baja relevancia clínica debido a la reducida magnitud del efecto. Si bien la selección del fármaco y el ajuste de dosis de acuerdo con los genotipos de los citocromos P450 están justificados, un gran número de pacientes necesitan ser genotipados para prevenir un caso de efecto secundario grave y/o no de respuesta. La disminución de los costos de los análisis genéticos modifica la relación costo-beneficio a favor de un aumento del empleo de las pruebas farmacogenéticas. Sin embargo, ellas tienen que combinarse con evaluaciones clínicas cuidadosas y otras herramientas (ej. monitoreo de drogas terapéuticas, fenotipado) para contribuir al objetivo general de proporcionar la mejor atención para los pacientes psiquiátricos.

Les facteurs génétiques influent sur la pharmacocinétique et la pharmacodynamique des médicaments, l’utilisation de tests pharmacogénétiques a déjà été proposée en psychiatrie dès le début des années 2000. Cependant, seuls quelques tests bénéficient de niveaux de preuve suffisants pour justifier leur utilisation en routine (par exemple, complexe majeur d’histocompatibilité, classe I, B, allèle 1502 [HLA-B*1502] pour la carbamazépine dans l’épilepsie et les troubles bipolaires); de nombreux résultats, lorsqu’ils sont reproduits, sont trop préliminaires ou n’ont finalement qu’une pertinence clinique limitée en raison de la faible amplitude de leur effet. Le choix des médicaments et l’adaptation posologique selon les génotypes des cytochromes P450 sont des démarches sensées mais il faut génotypier un grand nombre de patients pour prévenir un cas d’effet indésirable sévère et/ou d’absence de réponse. La diminution des coûts de l’analyse génétique a orienté le rapport coût/bénéfice vers une plus large utilisation des tests pharmacogénétiques. Ils doivent néanmoins être associés à un examen clinique soigneux et à d’autres moyens (par exemple, suivi thérapeutique des médicaments et phénomypage) afin d’apporter les meilleurs soins aux patients psychiatriques.

27. Rau T, Wohlleben G, Wutke H, et al. CYP2D6 genotypy: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. Clin Pharmacol Ther. 2004;75(5):386-393.
28. Penas-Lledo EM, Trejo HD, Dorado P, et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry. 2013;18(1):8-9.
29. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008;3(4):e1872.
30. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008;30(4):474-482.
31. Serretti A, Calati R, Massat I, et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol. 2009;24(5):250-256.
32. Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 2 studies in major depressive disorder. J Clin Psychiatry. 2010;71(11):1482-1487.
33. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53(9):801-811.
34. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-1341.
35. Hicks JK, Bishop JR, Sanghkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127-134.
36. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:224.
37. Eap CB, Crettol S, Rouger JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81(5):719-728.
38. Dobrinas M, Crettol S, Oneda B, et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics. 2013;23(2):84-93.
39. Ansermot N, Albayrak O, Schlapfer J, et al. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med. 2010;170(6):529-536.
40. Allorge D, Chevalier D, Lo-Guidice JM, et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol. 2003;56(3):341-344.
41. Eap CB, Bender S, Jaquenoud Siroet E, et al. Nonresponse to clozapine and ultrarapid CYP2A6 activity: Clinical data and analysis of the CYP2A6 gene. Br J Clin Pharmacol. 2004;58(3):214-219.
42. Dobrinas M, Cornuz J, Pedrido L, Eap CB. Influence of cytochrome P450 2D6 genotypes on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics. 2012;22(2):143-151.
43. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90(1):117-125.
44. Thorn CF, Akiliu E, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012;22(1):73-77.
vascular risk factors in bipolar disorder equals that of schizophrenia: a

Res.

drome in patients with schizophrenia: baseline results from the Clinical

61.

60.

58.

studies.

57.

55.

Psychiatry.

54.

53.

response to antidepressant treatment.

52.

pharmacogenetic findings in major depressive disorder.

51.

Kato M, Serretti A. Review and meta-analysis of antidepressant
efficacy.

50.

Porcelli S, Fabbrri C, Serretti A. Meta-analysis of serotonin transporter
gene promoter polymorphism (5-HTTLPR) association with antidepressant
efficacy. Eur Neuropsychopharmacol. 2012;22(4):239-258.

49.

Choong E, Dobrinas M, Carrupt PA, Eap CB. The permeability glyco-
protein: a focus on enantioselectivity and brain distribution. Expert Opin
Drug Metab Toxicol. 2010;6(8):953-965.

48.

Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of
midazolam (75 micrograms) as an in vivo probe for CYP3A activity. Eur J
Clin Pharmacol. 2004;60:237-246.

47.

Hogdes LM, Markova SM, Chinn LW, et al. Very important pharmaco-
cogenene summary: ABCB1 (MDR1), P-glycoprotein. Pharmacogenet Genomics
2011;2(12):75-81.

46.

Choong E, Dobrinas M, Carrupt PA, Eap CB. The permeability glyco-
protein: a focus on enantioselectivity and brain distribution. Expert Opin
Drug Metab Toxicol. 2010;6(8):953-965.

45.

Bosilkovska M, Samer CF, Deglon J, et al. Geneva cocktail for cyto-
chrome p450 and P-glycoprotein activity assessment using dried blood
spots. Clin Pharmacol Ther. 2014;96(3):349-359.

44.

Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazol-
am in CYP3A4- and CYP3A5- genotyped subjects. Eur J Clin Pharmacol.
2004;60(4):231-236.

43.

5.

Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardio-
vascular risk factors in bipolar disorder equals that of schizophrenia: a
comparative study. J Clin Psychiatry. 2007;68(6):917-923.

63.

Cohn TA, Remington G. Risk factors for coronary heart disease in lon-
ter term patients on antipsychotic medication: high prevalence of syn-
drome X. Schizophren Res. 2003;60(1):353-354.

62.

Baln SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J. Mecha-
nisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol
Ther. 2011;90(1):179-183.

61.

Leuch T, Wallace TJ, Chowdhury Nl, Tiwari AK, Kennedy JL, Muller DJ.
Pharmacogenetics of antipsychotic-induced weight gain: review and clin-
cal implications. Mol Psychiatry. 2012;17(3):242-266.

60.

Choo E, Quteineh L, Cardinaux JR, et al. Influence of CRTCI poly-
morphisms on body mass index and fat mass in psychiatric patients
and in the general adult population. JAMA Psychiatry. 2013;70(10):1011-
1019.

59.

Quteineh L, Vandenberge F, Saii Morgui N, et al. Impact of HSD11B1
polymorphisms on BMI and components of the metabolic syndrome in
patients receiving psychotropic treatments. Pharmacogenet Genomics.
2015;25(5):246-258.

58.

Delacrétaz A, Preisig M, Vandenberge F, et al. Influence of MCHR2
and MCHR2-ASTI genetic polymorphisms on body mass index in psychiatric
patients and in subjects from the general population with present or past
atypical depression. PLoS One. 2015;10(10):e0139155.

57.

Saii Morgui N, Vandenberge F, Delacrétaz A, et al. Association of
PKCI with body mass index and other metabolic features in patients
with psychotropic treatments. J Clin Psychopharmacol. 2015;35(5):544-552.

56.

Brandi EJ, Tiwari AK, Zai CC, et al. Genome-wide association study on
antipsychotic-induced weight gain in the CATIE sample. Pharmacogenet
Genomics. 2015 Sep 1. Epub ahead of print. doi:10.1038/tjp.2015.59.

55.

Saigi Morgui N, Vandenberge F, Delacrétaz A, et al. Association of
genetic risk scores with body mass index in Swiss psychiatric cohorts. Phar-
cogenet Genomics. 2016;26(5):208-217.

54.

Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamaze-
pine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics.
2006;16(4):297-306.

53.

Leckband SG, Kelsoe JR, Dunnbennger HM, et al. Clinical Pharmacal-
genetics Implementation Consortium guidelines for HLA-B genotype and
carbamazepine dosing. Clin Pharmacol Ther. 2013;94(3):324-328.

52.

Chen CH, Lee CS, Lee MT, et al. Variant GADD1 response to lithium
therapy in bipolar I disorder. N Engl J Med. 2014;370(2):119-128.

51.

Wong ML, Dong C, Flores DL, et al. Clinical outcomes and genome-wide
association for a brain methylation site in an antidepressant pharmacoge-
genetics study in Mexican Americans. Am J Psychiatry. 2014;171(6):1297-1309.

50.

Porcelli S, Fabbrri C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genet-
ics and antidepressant: where we are. Clin Neuropsychopharmacol. 2011;8(2):99-150.

49.

McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syn-
drome in patients with schizophrenia: baseline results from the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia
trial and comparison with national estimates from NHANES III. Schizophr
Res. 2005;80(1-3):19-32.

48.

Birknes AB, Opjordsmoen S, Brunborg C, et al. The level of cardio-
vascular risk factors in bipolar disorder equals that of schizophrenia: a
comparative study. J Clin Psychiatry. 2007;68(6):917-923.

47.

Menke A, Binder EB. Epigenetic alterations in depression and antide-
pressant treatment. Dialogues Clin Neurosci. 2014;16(3):395-404.